Volpara (ASX:VHT) share price pushes higher on record quarterly update

The company provided investors with its latest performance report.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Volpara Health Technologies Ltd (ASX: VHT) share price is climbing today following the release of the company's quarterly report.

At the time of writing, the healthcare technology company's shares are up 1.17% to $1.295.

a smiling doctor looks at her computer screen with medical imaging X-rays on a light screen in the background.

Image source: Getty Images

How did Volpara perform for Q2 FY22?

According to its release, Volpara advised record sales and cash inflows for the 3 months ending 30 September.

In particular, cash receipts from customers totalled NZ$7.1 million (A$6.79 million), an increase of 11% on the previous quarter. Compared against the prior corresponding period, this metric grew 52% — or 68% in constant currency terms.

Subscription-based receipts continued to accelerate, representing more than NZ$6.9 million (A$6.60 million) for the 3 months. This is a jump of 63% year-on-year, or roughly 74% in constant currency.

Net operating cash outflow came to NZ$3.8 million (A$3.63 million), consistent with Q2 FY21. Some material supplier contract renewals, such as its annual insurance program, kept the costs in line.

Volpara noted that it closed the quarter with cash of NZ$25 million (AS23.91) on hand and no debt.

On the Software-as-a-Service (SaaS) front, annual recurring revenue (ARR) stood at US$20.4 million (A$27.24) million. Contracts were signed across the company's full product suite as both standalone sales and platform deals. Many existing customers also increased contracts with Volpara whether by adding on products or expanding use of existing products.

The average revenue per user (ARPU) improved to US$1.46 (A$1.95), up 5% on the prior quarter. Its legacy MRS support contracts were heavily weighted towards the lower ARPU ranges, while its subscription-based products weighted more to the higher ARPUs.

Volpara group CEO Dr Ralph Highnam commented:

Q2 is traditionally our weakest quarter for sales, and yet today we've shown that we've had a record quarter not only for sales but also cash inflows.

…Our job now is to keep that momentum and passion for what we do as we go through the second half of the year, keeping in mind potential winter waves of COVID in the northern hemisphere.

Volpara share price summary

The past 12 months have been a disappointing run for investors, with the company's shares down almost 11%. When looking at year-to-date, its losses are hovering around 9% over the period.

Based on today's price, Volpara presides a market capitalisation of roughly $329 million and has approximately 251.3 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended VOLPARA FPO NZ. The Motley Fool Australia owns shares of and has recommended VOLPARA FPO NZ. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A cool white-bearded man holds his hand up signalling you should halt.
Healthcare Shares

ASX 300 cannabis stock Incannex suspended ahead of 'material update'

The Incannex share price is frozen at 14 cents for now.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

Guess which ASX All Ords stock is rocketing 27% on a new FDA approval

Rett Syndrome has finally got an approved treatment.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

Buy these excellent ASX 200 healthcare shares: Goldman Sachs

Goldman has spoken very positively about these healthcare shares this week.

Read more »

medical asx share price represented by doctor giving thumbs up
Healthcare Shares

Guess which ASX biotech stock just rocketed 29% on big FDA news

The ASX healthcare share is attracting investor interest following FDA approval for its targeted cancer therapy compound.

Read more »

A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

Should I buy CSL shares while they're under $300?

Can investors make a healthy return with this biotech?

Read more »

A man wearing a white coat holds his hands up and mouth open with joy.
Healthcare Shares

Mesoblast share price rockets 23% on FDA news

Mesoblast has received some good news for the US FDA this morning.

Read more »

A young woman wearing a blue blouse with white polkadots holds her phone up with an intrigued and happy look on her face as she reads some news.
Healthcare Shares

Owners of this ASX 200 share are soon going to receive a bigger dividend

Investors in this healthcare company are about to get a healthy cash boost.

Read more »

an older couple look happy as they sit at a laptop computer in their home.
Healthcare Shares

Hoping to collect the latest CSL dividend? Here's how

The next CSL dividend is fast approaching.

Read more »